Plain-English translation of NCT06398418 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a probiotic supplement called in combination with immunotherapy drugs you may already be taking for advanced cancer. Researchers believe that might help your immune system work better against your tumor by changing the balance of bacteria in your gut. The trial will measure how safe the medication is, how much of it stays in your body, and whether it helps slow or shrink your cancer.
Many patients with advanced melanoma and other solid tumors stop responding to standard immunotherapy drugs over time. This trial exists to see whether adding this probiotic treatment might help restart your immune system's ability to fight cancer and give patients another option when initial treatments stop working.
You likely qualify if…
You likely don't qualify if…
You will take the probiotic supplement by mouth as a daily oral medication while continuing your existing immunotherapy treatment. Throughout the trial, you'll have regular visits where doctors will examine your tumors using imaging scans (CT or MRI), check your blood work, and collect stool samples to see how the treatment is affecting inflammation and the bacteria in your gut. You'll also be asked to report how you're feeling overall, so doctors can track both the benefits and any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Rise Therapeutics LLC
Enrollment target
~33 participants
Started
August 2025
Primary completion
April 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Janet Stephens, PhD
Rise Therapeutics LLC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.